{"organizations": [], "uuid": "532996b56a7181af358b3bc1c4de74852dd69562", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sensorion-fy-operating-loss-widens/brief-sensorion-fy-operating-loss-widens-to-9-5-million-euros-idUSASC09VMT", "country": "US", "domain_rank": 408, "title": "BRIEF-Sensorion FY Operating Loss Widens To 9.5 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T08:37:00.000+03:00", "replies_count": 0, "uuid": "532996b56a7181af358b3bc1c4de74852dd69562"}, "author": "", "url": "https://www.reuters.com/article/brief-sensorion-fy-operating-loss-widens/brief-sensorion-fy-operating-loss-widens-to-9-5-million-euros-idUSASC09VMT", "ord_in_thread": 0, "title": "BRIEF-Sensorion FY Operating Loss Widens To 9.5 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 5:38 AM / in 11 minutes BRIEF-Sensorion FY Operating Loss Widens To 9.5 Million Euros Reuters Staff \nApril 12 (Reuters) - SENSORION SA: * SENSORION REPORTS FULL YEAR 2017 RESULTS \n* CASH AND CASH EQUIVALENTS AT END PERIOD EUR 7.6 MILLION VERSUS EUR 8.5 MILLION YEAR AGO \n* FY OPERATING LOSS OF EUR 9.5 MILLION VERSUS LOSS OF EUR 8.4 MILLION YEAR AGO \n* 2018 OUTLOOK: PHASE II CLINICAL DATA FOR LEAD DRUG-CANDIDATE, SENS-111 \n* 2018 OUTLOOK: INITIATION OF PHASE II CLINICAL TESTING FOR SENS-401 \n* SENS-401: PLANS PHASE 2 CLINICAL TRIAL IN CHEMOTHERAPY-TREATED PAEDIATRIC PATIENTS, MAY START AT BEGINNING OF 2019 \n* FY NET LOSS OF EUR 9.7 MILLION VERSUS LOSS OF EUR 8.9 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-04-12T08:37:00.000+03:00", "crawled": "2018-04-12T08:53:07.009+03:00", "highlightTitle": ""}